DeveloGen Announces Changes to Scientific Advisory Board

Goettingen, Germany - January 11th, 2006: DeveloGen, a biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs for the treatment of metabolic disorders, today announced the appointment of Alexander Fleming, MD, as a member of its Scientific Advisory Board. DeveloGen further announced that Prof. Jean-François Bach, has resigned from DeveloGen’s Scientific Advisory Board at the end of 2005 due to his election as permanent secretary of the Académie des Sciences, France.

Dr. Guenther Karmann, Chief Executive Officer of DeveloGen, said: “We are delighted to have Dr. Alexander Fleming join our Scientific Advisory Board. DeveloGen’s clinical programs will greatly benefit from Dr. Fleming’s expertise in endocrinology, clinical drug development and his intimate knowledge of the FDA regulatory process. We would like to thank Prof. Bach for his long-standing valued contribution to the company.”

Dr. G. Alexander Fleming, stated: “I am honored and excited to be part of the Scientific Advisory Board of DeveloGen. I very much look forward to contributing to the advancement of the company’s lead product, DiaPep277®, because of its excellent prospects for becoming the first approved therapy for the underlying cause of type 1 diabetes. Equally exciting is the opportunity to help advance the company’s very impressive pipeline of innovative therapeutic compounds for the treatment of metabolic disorders.”

During his tenure at the United States Food and Drug Administration (FDA) as reviewer, medical team leader, and innovator, Dr. Fleming helped shape regulatory policy, review processes, and reviewer professionalism for over a decade. In addition to his knowledge of international affairs and good clinical practice, Dr. Fleming brings to DeveloGen his extensive experience in FDA regulatory matters for metabolic and endocrine disorders, combined with a deep understanding of the clinical drug development process in general.

The Scientific Advisory Board of DeveloGen comprises five internationally recognized scientists and clinicians who contribute vast experience and expertise in the discovery and development of drugs for metabolic disorders, such as type 1 and type 2 diabetes as well as diabetic complications. In particular, drug discovery aspects are supported by Profs. Herbert Jaeckle, Michael Sela and Herbert Waldmann, whereas clinical development is strengthened by Dr. G. Alexander Fleming and Prof. Hubert Kolb.

DeveloGen

DeveloGen is a biopharmaceutical company engaged in the discovery and development of novel therapeutic drugs for the treatment of metabolic disorders, such as type 1 and type 2 diabetes as well as diabetic complications. DeveloGen has a broad and innovative pipeline with its most advanced drug candidate, DiaPep277®, currently being evaluated in Europe in a phase III clinical trial for type 1 diabetes in newly diagnosed adult patients. Further Diapep277 is being explored in phase II clinical trials and a phase IIb/III clinical trial for Latent Autoimmune Diabetes in Adults (LADA) patients. In its beta-cell regeneration program for type 1 and type 2 diabetes, the company is pursuing a series of lead structures, such as secreted factors and small molecule Pax4 inhibitors, aimed at regenerating the body’s own beta-cells. Somatoprim, a therapeutic drug candidate for the potential treatment of diabetic complications, is in pre-clinical development. Moreover, as part of its efforts to discover novel treatments for type 2 diabetes and obesity, DeveloGen has identified a number of broadly validated novel targets and is pursuing further development of lead structures for several of these targets. DeveloGen is headquartered in Goettingen, with additional sites in Rehovot, Israel, and Erkrath, Germany. For more information on DeveloGen, please visit our website at www.develogen.com.

Contact Information

Kathrin Shem-Tov

Manager Corporate Affairs

DeveloGen AG

Contact via E-mail